Atrial tachyarrhythmias in primary and secondary prevention ICD recipients: Clinical and prognostic data

PACE - Pacing and Clinical Electrophysiology

Volumn 29, Issue SUPPL. 2, 2006, Pages

  Botto, Giovanni Luca ^a   Luzi, Mario ^a   Ruffa, Franco ^a   Russo, Giovanni ^a   Ferrari, Giovanni ^a  

^a SANT ANNA HOSPITAL   (Italy)

Author keywords

Atrial fibrillation; Atrial tachycardia; Implantable cardioverter defibrillator; Sudden death prevention

Indexed keywords

AGE; ARTICLE; CARDIOVERSION; CLINICAL EXAMINATION; DEFIBRILLATION; DEFIBRILLATOR; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE FUNCTION; HUMAN; IMPLANTATION; MORTALITY; PREVALENCE; PRIMARY PREVENTION; PROGNOSIS; REGISTER; RISK ASSESSMENT; SECONDARY PREVENTION; SUDDEN DEATH; TREATMENT INDICATION;

ATRIAL FIBRILLATION; CLINICAL TRIALS; DISEASE-FREE SURVIVAL; ELECTRIC COUNTERSHOCK; HUMANS; PRIMARY PREVENTION; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33751369512     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2006.00489.x     Document Type: Article

References (48)

1. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995; 155:469-574.
2. Go AS, Hylek EM, Phillips KA, Chang YC, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults. National implication for rhythm management and stroke prevention: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 2001; 285:2370-2375.
3. Stevenson WG, Stevenson LW. Atrial fibrillation in heart failure. N Engl J Med 1999; 341:910-911.
4. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure in patients with asymptomatic and symptomatic left ventricular dysfunction:Aretrospective analysis of the SOLVD trials. J Am Coll Cardiol 1998; 32:695-703.
5. Middlekauff HR, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure: A study of 390 patients. Circulation 1991; 84:40-48.
6. Nattel S. Newer developments in the management of atrial fibrillation. Am Heart J 1995; 130:1094-1106.
7. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, et al. Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure survey programme - A survey on the quality of care among patients with heart failure in Europe. Part 1: Patient characteristics and diagnosis. Eur Heart J 2003; 24:442-463.
8. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation. Chest 2004; 126:S429-S456.
9. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998; 98:946-952.
10. Carson PE, Johnson GR, Dunkman WB, Fletcher RD, Farrell L, Cohn JN. The influence of atrial fibrillation in prognosis on mild to moderate heart failure. The V-HeFT Studies. Circulation 1993; (Suppl. VI): VI102-VI110.
11. Maysel WH, Stevenson LW. Atrial fibrillation in heart failure: Epidemiology, pathophysiology and rationale for therapy. Am J Cardiol 2003; 91(Suppl.):2D-8D.
12. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, D'Agostino RB, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham Heart Study. Circulation 2003; 107:2920-2925.
13. Clark DM, Plumb VJ, Epstein AE, Kay GN. Hemodynamic effect of irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol 1997; 30:1039-1045.
14. Grogan M, Smith HC, Gersh BJ, Wood DW. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992; 69:1570-1575.
15. Shinbane JS, Wood MA, Jensen DN, Ellenbogen KA, Fitzpatrick AP, Scheinman MM. Tachycardia-induced cardiomyopathy: A review of animal models and clinical studies. J Am Coll Cardiol 1997; 29:709-715.
16. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary. A report of the America College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences. J Am Coll Cardiol 2001; 38:1266i-1266ixx.
17. Ryan S, Siemon G, Drogemuller A, Rameken M, Vater M, Seges J, Seidl. Two-year follow-up of 321 patients with an implantable cardioverter/ defibrillator: Comparison with and without atrial fibrillation. Z Kardiol 2001; 90:906-915.
18. Deneke T, Lawo T, Gerritse B, Lemke B, for the European GEM DR Investigators. Mortality of patients with implanted cardioverter/defibrillators in relation to episodes of atrial fibrillation. Europace 2004; 6:151-158.
19. Dries DL, Rosenber YD, Waclawiw MA, Domanski MJ. Ejection fraction and the risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: Evidence of gender differences in SOLVD trial. J Am Coll Cardiol 1997; 29:1074-1080.
20. Khran AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: Incidence, risk factors and prognosis in the Manitoba follow-up study. Am J Med 1995; 98:476-484.
21. Vidaillet H, Granada JF, Chyou PH, Maassen K, Ortiz M, Pulido JN, Sharma P, et al. A population-based study on mortality among patients with atrial fibrillation or flutter. Am J Med 2002; 113:365-370.
22. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risk associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley Study. Am J Med 2002; 113:359-364.
23. The Antiarrhythmic Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997; 337:1576-1583.
24. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillator in patients resuscitated from cardiac arrest. Circulation 2000; 102:748-754.
25. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, Mitchell LB, et al. Canadian Implantable Defibrillator Study (CIDS): A randomized trial of the implantable defibrillator against amiodarone. Circulation 2000; 102:748-754.
26. Connolly SJ, Hallstrom P, Cappato R, Schron EB, Kuck KH, Zipes DP, Greene HL, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. Eur Heart J 2000; 21:2071-2078.
27. Lee DS, Green LD, Liu PP, Dorian P, Newman DM, Grant FC, Tu JV, et al. Effectiveness of implantable defibrillators for preventing arrhythmic events and death: A meta-analysis. J Am Coll Cardiol 2003; 41:1573-1582.
28. Ezekowitz JA, Amstrong PW, McAlister FA. Implantable cardioverter defibrillators in primary and secondary prevention: A systematic review of randomized controlled trials. Ann Intern Med 2003; 138:445-452.
29. Gregoratos G, Abrams J, Epstein AE, Freedman RA, Hayes DL, Hlatky MA, Kerber RE, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines/North American Society for Pacing and Electrophysiology Committee to Update the 1998 Pacemaker Guidelines. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and arrhythmia devices: Summary article. Circulation 2002; 106:2145-2161.
30. Oseroff O, Retyk E, Bochoeyer A. Subanalyses of secondary prevention implantable cardioverter-defibrillator trials: Antiarrhythmic Versus Implantable Defibrillators (AVID), Canadian Implantable Defibrillator Study (CIDS), and Cardiac Arrest Study Hamburg (CASH). Curr Opin Cardiol 2003; 19:26-30.
31. Hallstrom AP, McAnulty JH, Wilkoff BL, Follmann D, Raitt MH, Carlson MD, Gillis AM, et al. Antiarrhythmics Versus Implantable Defibrillator (AVID) Trial Investigators. Patients at lower risk of arrhythmia recurrence: A subgroup in whom implantable defibrillators may not offer benefit. J Am Coll Cardiol 2001; 37:1093-1099.
32. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, et al. Improved survival with an implantable defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996; 335:1933-1940.
33. Bigger JT, for the CABG-Patch Trial Investigators. Prophylactic use of the implantable cardioverter defibrillator in patients at high risk for ventricular arrhythmias after coronary artery by-pass graft surgery. N Engl J Med 1997; 337:1569-1575.
34. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999; 341:1882-1890.
35. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, et al. Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346:877-883.
36. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, Fain E, et al. DINAMIT Investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004; 351:2481-2488.
37. Bansch D, Antz M, Boczor S, Volkmer M, Tebbenjohanns J, Seidl K, Block M, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: The Cardiomyopathy Trial (CAT). Circulation 2002; 105:1453-1458.
38. Strickberger SA, Hummel JD, Bartlett TG, Frumin HI, Schuger CD, Beau SL, Bitar C, et al. AMIOVIRT Investigators. Amiodarone versus implantable cardioverter-defibrillator: Randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia - AMIOVIRT. J Am Coll Cardiol 2003; 41:1707-1712.
39. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, Calkins H, et al. Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004; 350:2151-2158.
40. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, et al. Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350:2140-2150.
41. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverterdefibrillator for congestive heart failure. N Engl J Med 2005; 352:225-237. Erratum in: N Engl J Med 2005; 352:2146.
42. Nathakumar K, Epstein AE, Kay GN, Plumb VJ, Lee DS. Prophylactic implantable defibrillator therapy in patients with left ventricular systolic dysfunction. A pooled analysis of 10 primary prevention trials. J Am Coll Cardiol 2004; 44:2166-2172.
43. Greenberg H, Case RB, Moss AJ, Brown MW, Carroll ER, Andrews ML, for the MADIT-II investigators. Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II). J Am Coll Cardiol 2004; 43:1459-1465.
44. Moss A. Late breaking trial at the 23rd North American Society of Pacing and Electrophysiology meeting 2002.
45. Baldasseroni S, De Biase L, Fresco C, Marchionni N, Marini M, Masotti G, Orsini G, et al. Italian Network on Congestive Heart Failure. Cumulative effect of complete left bundle-branch block and chronic atrial fibrillation on 1-year mortality and hospitalization in patients with congestive heart failure. A report from the Italian network on congestive heart failure (in-CHF database). Eur Heart J 2002; 23:1692-1698.
46. Kim SG, Hallstrom A, Love JC, Rosenberg Y, Powell J, Roth J, Brodsky M, et al. Comparison of clinical characteristics and frequency of implantable defibrillator use between randomized patients in the Antiarrhythmic Versus Defibrillators (AVID) Trial and nonrandomized registry patients. Am J Cardiol 1997; 80:454-457.
47. Gradaus R, Block M, Brachmann J, Breithardt G, Huber HG, Jung W, Kranig W, et al. German EURID Registry. Mortality, morbidity and complications in 3344 patients with implantable cardioverter defibrillators: Results from the German ICD Registry EURID. Pacing Clin Electrophysiol 2003; 26:1511-1518.
48. Boriani G, Santini M, Proclemer A, Lunati M, Rauhe W, Mazzini E, Santi E, et al. Primary prevention of sudden death in post-infarction patients using cardioverter-defibrillators: Results on 444 patients from a multicenter national registry (abstract). Eur Heart J 2005; 26(Suppl.):653.